Advertisement
Advertisement
GYRE
Gyre Therapeutics, Inc. Common Stock
4.76
USDSponsored
+0.75
+18.70%
Nov 06, 15:59 UTC -5
Closed
After-Market
4.76
0.00
0.00%
Gyre Therapeutics, Inc. Common Stock (GYRE) Earnings
GYRE Earnings Reports
Positive Surprise Ratio
GYRE beat 17 of 36 last estimates.
47%
Next Report
Date of Next Report
Nov 18, 2026
Estimate for Q3 26 (Revenue/ EPS)
$28.97M
/-$0.12
Implied change from Q2 26 (Revenue/ EPS)
-0.47%
/--
Implied change from Q3 25 (Revenue/ EPS)
-5.22%
/-250.00%
Gyre Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 07, 2026, GYRE reported earnings of -0.12 USD per share (EPS) for Q2 26, missing the estimate of -0.09 USD, resulting in a -30.72% surprise. Revenue reached 29.11 million, compared to an expected 27.02 million, with a 7.72% difference. The market reacted with a +4.22% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of -0.12 USD, with revenue projected to reach 28.97 million USD, implying an increase of 0.00% EPS, and decrease of -0.47% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
FAQ
What were Gyre Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Gyre Therapeutics, Inc. Common Stock reported EPS of -$0.12, missing estimates by -30.72%, and revenue of $29.11M, 7.72% above expectations.
How did the market react to Gyre Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 4.22%, changed from $6.40 before the earnings release to $6.67 the day after.
When is Gyre Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 18, 2026.
What are the forecasts for Gyre Therapeutics, Inc. Common Stock's next earnings report?
Based on 4
analysts, Gyre Therapeutics, Inc. Common Stock is expected to report EPS of -$0.12 and revenue of $28.97M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.